Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334815 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Phase 2 study of Lung Adenocarcinoma and Stage IIIA Lung Non-Small Cell Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT00334815 is a Phase 2 study of Lung Adenocarcinoma and Stage IIIA Lung Non-Small Cell Cancer AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants, below the 557-participant average among 14 other Lung Adenocarcinoma trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00334815, a Phase 2 study of Lung Adenocarcinoma and Stage IIIA Lung Non-Small Cell Cancer AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with radiation therapy and bevacizumab may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Etoposide
- BIOLOGICAL Filgrastim
- BIOLOGICAL Bevacizumab
Study Locations (20)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Fremont - Rideout Cancer Center - Marysville
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Comprehensive Cancer Center - Sacramento
- Providence Santa Rosa Memorial Hospital - Santa Rosa
- Gene Upshaw Memorial Tahoe Forest Cancer Center - Truckee
- Northbay Cancer Center - Vacaville
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
- UCHealth University of Colorado Hospital - Aurora
- Denver Health Medical Center - Denver
- University of Colorado - Denver
- Shaw Cancer Center - Edwards
- Valley View Hospital Cancer Center - Glenwood Springs
- Montrose Memorial Hospital - Montrose
Arkansas
- Saint Bernards Regional Medical Center - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Rogers - Rogers
Alabama
- Providence Hospital - Mobile
Florida
- Cancer Centers of Central Florida PA - Leesburg
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-06-15 |
| Est. Completion | 2026-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334815
The ClinicalTrials.gov registry entry for NCT00334815 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 557-participant average among 14 other Lung Adenocarcinoma trials with a reported enrollment target (95% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Lung Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT00334815 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00334815 about?
NCT00334815 is a clinical study titled "Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery". This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways t...
What is the current status of trial NCT00334815?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2006-06-15. Estimated completion is 2026-02-22.
What conditions does trial NCT00334815 study?
This clinical trial studies the following conditions: Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma.
What interventions are being tested in trial NCT00334815?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Filgrastim (BIOLOGICAL), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00334815?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334815 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
RECRUITING · NA
-
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
RECRUITING · Phase 1
-
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Lung Adenocarcinoma
All registered trials for this condition
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.